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Women develop exercise-associated hyponatremia (EAH) more frequently than do men, which has been attributed to their lower body weight and size, excess water ingestion, and longer racing times (1, 20) . While these factors contribute to the greater incidence of hyponatremia in women, it is likely that their greater estrogen and progesterone exposure also plays a role in increasing the risk of symptomatic hyponatremia in women. It has been proposed that arginine vasopressin (AVP) plays a role in sex differences. The study of brain cell water regulatory function is limited in humans, but studies in our laboratory have shown that high levels of estradiol and progesterone lead to an earlier threshold for the osmotic release of AVP (21, 22, 24, 25) , as well as generalized changes in osmoregulation of AVP and water balance (2, 4, 5, 28) . Studies in rats reveal that in response to increasing hypotonic water retention AVP increases brain capillary and cerebroventricular ependymal cell water permeability through aquaporin (AQP4) channels regulated via AVP-V 1 receptors (6) . This alteration in cell water permeability leads to increases in intracellular astrocyte sodium and water. In male animals, the Na ϩ -K ϩ -ATPase pump acts to extrude Na ϩ out of astrocytes to normalize volume (7) . However, this Na ϩ -K ϩ -ATPase pump action is slowed in females, because estrogens can block astroglia regulatory volume decreases, resulting in greater water remaining within the cells (7) . Thus the hypothesis has been proposed that inappropriately high AVP levels in plasma and tissue not only contribute to the onset of hyponatremia, but also to its damaging consequences in the brain (19, 20, 27) .
Alternative hypotheses, such as that excessive sodium loss through sweating or greater water retention from drinking contribute to hyponatremia, have not been explored in women susceptible to EAH. Exposure to estrogens can alter sodium regulation during exercise (24) and during hypertonic saline infusion (22) , resulting in a modest sodium retention (22, 25) . However, while sex differences in the risk for EAH suggest a role for sex hormones on sodium regulation, these hormone effects on the regulation of electrolytes and fluids have not been explored in women at known risk for EAH. The purpose of this study was to examine body water and sodium regulation in women at high risk for EAH during endurance exercise. We hypothesized that women at risk for EAH would retain more fluid and lose more sodium compared with women at low risk for EAH. We further hypothesized that estradiol exposure, with and without progesterone, would increase water retention and sodium loss in women at high risk for EAH.
METHODS
We recruited 16 subjects: 7 women had experienced at least one episode of hyponatremia as diagnosed by their physician or medical race personnel [Hypo, 24 yr (SD 4)], and 9 women had never had hyponatremia [no Hypo, 24 yr (SD 4)]. Recruitment into the Hypo group was not limited to women who have experienced exerciseassociated hyponatremia and included one woman with an episode of hyponatremia unrelated to exercise. All Hypo women had their condition diagnosed by a physician or, in the case of EAH, by race medical personnel. We included non-exercise-related cases to make recruitment more practical, and we felt this was justified because a prior episode indicated a risk for hyponatremia. Women were recruited through coaches at Yale University and medical staff at Yale University School of Medicine, through physicians at Yale-New Haven Hospital, and through advertisements. All women had normal menstrual cycles (26 -32 days) and had no contraindications to exercise or to our hormone treatments (see below). All subjects were interviewed to obtain their medical history and gave written informed consent to participate in the study, which had prior approval by the Human Investigation Committee of Yale University School of Medicine.
Experimental design. Each subject participated in three exercise sessions, one during gonadotropin-releasing hormone (GnRH) antagonist alone, one while taking GnRH antagonist with estradiol (E 2), and one while taking GnRH antagonist with estradiol ϩ progesterone (E 2-P4). To suppress reproductive function for the duration of the study, the subjects received the GnRH antagonist, ganirelex acetate (250 g/day, Antagon, Organon, West Orange, NJ), each day for 16 days ( Fig. 1) . Beginning on the fifth day of GnRH antagonist administration, the women received 11 days of estrogen administration (17␤-estradiol, 2 transdermal patches, 0.1 mg/day each, Mylan Pharmaceuticals, Morgantown, WV). Beginning on the 12th day of GnRH antagonist administration, the women added 200 mg/day of oral progesterone (Prometrium, Solvay Pharmaceuticals, Marrietta, GA) for 4 days. Experimental protocols were performed following 48 h of GnRH antagonist administration, on the 9th day (GnRH antagonist with estrogen), and again on the 16th day of administration (GnRH antagonist with estrogen and progesterone). This design permitted between-group comparisons of our exercise and drinking protocol on women with and without the risk of EAH, as well as within-subject comparisons concerning estrogen and progesterone effects on fluid regulation during exercise and drinking in both groups. This hormonesuppression, add-back design eliminated other potential confounders such as GnRH and the gonadotropins (follicle-stimulating hormone, luteinizing hormone), thus providing a direct assessment of the estradiol and progesterone influences on our outcome variables.
GnRH antagonist (ganirelex acetate). Ganirelix acetate is a synthetic decapeptide with high antagonistic activity against naturally occurring GnRH. Ganirelix acetate is derived from native GnRH with substitutions at positions 1, 2, 3, 6, 8, and 10. When ganirelix acetate is given in therapeutic doses it acts by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transductions pathway. It induces a rapid, reversible suppression of gonadotropin secretion (16, 17) . In young, cycling women, continued administration of ganirelix acetate leads to suppression of estrogen and progesterone to postmenopausal levels ( Fig. 1) . These decreases occur after 36 -48 h of administration, and the suppression of the hypothalamicpituitary-ovarian axis is reversed on cessation of drug therapy (16, 17) .
The GnRH antagonist administration began 9 -10 days following the subject's luteinizing hormone peak. This peak precedes ovulation, usually days 12-14 of a 28-day menstrual cycle, and was determined individually by the use of ovulation prediction kits (OvuQuick, Quidel, San Diego, CA). One of the subjects (no Hypo) was taking oral contraceptives. She ceased taking the pills and began GnRH antagonist administration on day 21 of the pill cycle. The subjects self-administered daily subcutaneous injections of the GnRH antagonist after training by qualified medical personnel. This method of GnRH antagonist administration was chosen because it is easily discontinued in the event of uncomfortable side effects, such as headaches or "hot flashes," and the suppression of the hypothalamicpituitary-ovarian axis is rapidly reversed on cessation of drug therapy.
Peak oxygen consumption. During the early follicular phase of the menstrual cycle preceding the first body fluid regulation test, we used a continuous incremental exercise test to determine peak aerobic capacity (V O2peak) on the recumbent bicycle to be used in the body fluid regulation test. The subject began pedaling at 60 rpm at ϳ40% of her age-predicted peak heart rate (HR) for 3 min. Following this warmup period, the resistance on the bike was adjusted to increase HR by ϳ10 beats/min each stage, with pedaling rate remaining stable. All subjects were tested to volitional exhaustion meeting at least two of three criteria for determining V O2peak: a respiratory exchange ratio Ͼ 1.15; plateau of the oxygen consumption (V O2); or HR Ͼ agepredicted maximum [220 Ϫ age (yr)]. HR was continuously recorded from a Polar monitor (610i, Polar Electro, Oy, Finland) connected directly to a Parvo TrueOne 2400 metabolic cart (Parvo Medics, Sandy, UT). Oxygen consumption was determined by sampling expired gas fractions of CO2 and O2 from the Parvo metabolic cart. These measurements were corrected to standard conditions and used to determine V O2 at 20-s intervals throughout the test. All testing was supervised at the John B. Pierce Laboratory by trained exercise technicians.
Body fluid regulation testing. The subjects were instructed to refrain from alcohol and caffeine for 12 h before the experiment. In addition, the volunteers were asked to maintain their normal diet and level of activity for 3 days before the experimental protocols but refrain from heavy exercise for 48 h before the experiment. Because naive volunteers were used, they were brought to the laboratory before the experimental day, thoroughly trained in all maneuvers, and familiarized with all routines to ensure that they were as comfortable as possible on the first experimental day. Volunteers arrived at the Fig. 1 . Typical concentrations of plasma estradiol and progesterone over a normal menstrual cycle (top) and during treatment with gonadotropin-releasing hormone (GnRH) antagonist, followed by estradiol and progesterone (bottom).
laboratory at a specified time of day (ϳ8:00 AM). To reduce individual variability in hydration levels, subjects ate a controlled sodium and water diet (10 ml/kg body wt) the night before. The subjects arrived at the laboratory after having eaten a light, low-fat breakfast, and drank water (10 ml/kg body wt) ϳ60 min before beginning the experiment.
On arrival, the subject's exercise clothes (light nylon shorts, a sports bra, and socks) were weighed. The subject then changed into these clothes and gave a baseline urine sample. Hydration state was immediately assessed from urine specific gravity of the initial urine sample. If specific gravity was Ͼ1.02, or the subject was unable to provide a urine sample, she was given another 8 ml/kg of water to drink, followed by a 30-min rest period. When hydration level was deemed sufficient, the subject was weighed to the nearest 10 g on a beam balance and then sat on the contour chair (semirecumbent) of a cycle ergometer in the test chamber set at 27°C, 30 -40% relative humidity for 45 min to ensure a steady state in plasma volume and constituents. During this control period, the subject was instrumented for the measurement of HR and blood pressure. A 21-gauge Teflon catheter was placed in an antecubital or forearm vein with catheter patency maintained by a heparin block (20 U/ml). At the end of the 45-min control period, we measured baseline arterial blood pressure (Colin Medical Instruments, Komaki, Japan) and HR (Colin) for 10 min. We collected blood samples (25 ml) to determine hematocrit (Hct) and osmolality (P Osm) and concentrations of hemoglobin (Hb),
, and progesterone (P[P4]), where P refers to plasma and S refers to serum. Following the blood sample, the subject gave a preexercise urine sample and was then repositioned on the cycle ergometer while the chamber temperature was increased to 35°C (ϳ10 min).
The subject then exercised on the cycle ergometer in the semirecumbent position for 180 min in the 35°C environment at an estimated exercise intensity of 65% V O2peak for the first 60 min and 55-60% V O2peak for the final 120 min, based on the initial V O2peak test. During exercise, measurements were made of arterial blood pressure every 10 min, and HR was monitored continuously. During the first hour of exercise, blood was sampled (14 ml) every 15 min to determine changes in Hct, Hb, P[P], POsm, and P[AVP] and used to determine online plasma concentrations of sodium (iStat, Abbott, East Windsor, NJ). The subjects did not drink during the first hour of exercise. After the 60-min blood sample, the subject provided a urine sample, was weighed, and returned to the bicycle ergometer at which time she drank 8 ml/kg body wt in addition to the volume of water lost in the urine. During the final 120 min of exercise, ϳ0.2 ml of blood was drawn every 10 min to determine online blood concentrations of sodium (iStat). We also collected blood samples every 30 min (14 ml) to determine changes in Hct, Hb, P[P], POsm, and the concentrations of sodium, potassium, and AVP. We used these samples to determine serum electrolytes in our final analysis (flame photometry, see below). We determined concentrations of aldosterone and ANP from hourly samples (24 ml). Urine was analyzed for volume, specific gravity, osmolality, sodium, and potassium. During the final 120 min of exercise, immediately following all blood samples, the subjects drank 8 ml/kg body wt of tap water (16 ml ⅐ kg ⅐ Ϫ1 ⅐ h Ϫ1 ). In addition, the volume of water lost in the previous urine sample was replaced in the initial drink. The water was consumed as one drink with the subject given 10 min to finish drinking. Every 60 min, the subject stopped cycling, provided a urine sample, and was weighed. Following exercise, the subject was allowed to cool down and, as soon as possible, provided a urine sample. Exercise clothing was weighed immediately after exercise. Sweating rate was calculated with changes in body weight, corrected for fluid intake and urine output.
For sweat collection during exercise, two sweat collection patches were applied 15 min into each hour of exercise. Sealed absorbent patches (Pacific Biometrics, Seattle, WA) were placed on the chest and back for 20-to 25-min periods. The sweat patch consisted of 4.7 ϫ 3.1 cm filter paper, sealed, and was affixed to the skin with tegaderm (3M Medical Technologies, Minneapolis, MN). The area used for the patch was cleaned with deionized water before placement and wiped with a clean dry towel. Local sweat rate was determined by patch weight increase (to 0.0001 g) from the dry weight per minute on the skin. After weighing, the patches were transferred to plastic screw-capped bottles. The fluid in the patches was collected by centrifugation with nylon MicroFuge centrifuge filter tubes and analyzed for sodium and potassium concentrations.
Online measurements of electrolytes enabled us to continuously assess the sodium status of the subjects. For their safety, all volunteers were introduced to all procedures before actual testing and carefully supervised and monitored by a trained exercise technologist during the exercise testing itself. If blood sodium concentration fell by greater than 5 meq/l (n ϭ 2 in Hypo group), and/or fell below 128 meq/l (n ϭ 1 in Hypo group), the study was stopped. (One of the subjects whose blood sodium concentration fell by 5 meq/l had fallen to 128 meq/L, so the total stopped was 2 subjects.) These subjects were stopped in the final 30 min of exercise and were stopped at the same time during all three hormonal conditions. Likewise, if there had been significant weight gain (Ͼ1%), or any symptoms of hyponatremia, heat stress, or hypoglycemia, such as dizziness or excessive increases in heart rate, the study would have been stopped (this did not occur in either group).
Blood, urine, and sweat analysis. Blood samples were separated immediately into aliquots. The first was analyzed for hemoglobin and hematocrit. A second aliquot was transferred to a heparinized tube, a third added to a tube with no additive, and a final aliquot was placed in a prechilled tube containing EDTA. All tubes were centrifuged, and the plasma was taken off the heparinized sample and analyzed for osmolality, total protein, and AVP. The EDTA sample was analyzed for concentration of ANP, and the serum from the plain tube was analyzed for sodium, potassium, aldosterone, 17␤-estradiol, and progesterone.
Serum, sweat, and urine sodium and potassium were measured by flame photometry (Instrumentation Laboratory, model 943). Plasma and urine osmolality (U Osm) were assessed by freezing point depression (Advanced Instruments 3DII). Plasma and urine creatinine were determined by colorimetric assay (Sigma Diagnostic Products). Plasma concentrations of AVP, ANP, aldosterone, 17␤-estradiol, and progesterone were measured using radioimmunoassay techniques.
Plasma [ANP] was determined after extraction from plasma on octadecylsilane cartridges (SEP-PAK C18, Waters Associates, Marlborough, MA), and the eluate was collected with 4% acetic acid and 86% ethanol, with an incubation time with the antiserum of 24 h, followed by the addition of 125 I-ANP (ALPCO Diagnostics, Windham, NH). Anti-sheep (human) reagent was then used for separation of free and antibody-bound labeled ANP. Plasma [AVP] was determined after extraction from plasma by the methods described by Freund et al. (8, 9) on octadecylsilane cartridges (SEP-PAK C18, Waters Associates). Extracted samples were assayed using a disequilibrium assay with the extracts incubated with the antiserum at 4°C for 72 h followed by the addition of 125 I-arginine vasopressin (Perkin-Elmer Life Sciences, Boston, MA). Bovine albumin-coated charcoal was used for separation of free and antibody-bound labeled AVP. This assay is highly specific for AVP with the antiserum prepared against a lysine vasopressin-thyroglobin conjugate and has a sensitivity of 0.6 pg/ml. Extraction recovery of AVP was determined using plasma spiked with a known concentration of AVP (Peninsula Laboratories, Belmont, CA). The recovery sample was extracted and analyzed along with the subjects' samples. The extraction recovery was 87%.
Intra-and interassay coefficients of variation for the midrange standards were, respectively, as follows: P[AVP] (5.6 pg/ml) 10.2% and 11.5%, P[ANP] (29.8 pg/ml) 6.2% and 7.5% (Siemens Healthcare Diagnostics, Los Angeles, CA), P[ALD] (136 pg/ml) 1.5% and 1.8%, P[E2] (184 pg/ml) 0.8% and 1.7% (Diagnostic Products, Los Angeles, CA), and P[P4] (2.8 ng/ml) 0.9% and 2.3% (Siemens Healthcare Diagnostics).
Calculations. Total water loss due to dehydration was determined from body weight loss during the first hour of exercise. Total water loss or gain during the entire 180-min exercise bout was determined from body weight change, accounting for urine loss and used to determine total sweating rate in response to the exercise bout. During the final 2 h of exercise, net fluid gain during drinking was calculated by subtracting total urine and sweat loss from water intake, assuming that respiratory losses were negligible. Changes in plasma volume (PV) were estimated from changes in Hct and Hb from the control (preexercise) sample according to the equation:
in which subscripts a and b denote measurements at time a and control, respectively.
During the first hour of exercise, electrolyte losses in sweat and urine were calculated by multiplying the volume of water loss in each fluid by the concentration of the electrolyte within the fluid. Sweat electrolyte concentration was calculated from sweat rate and the average of local electrolyte concentrations in the chest and back. Sweat concentration of both sodium or potassium ([E] m) at each site was similar as determined by ANOVA. Electrolyte loss from sweat was calculated by multiplying [E] m and total body sweat loss, calculated from the change in body weight during each hour of exercise. To determine the cause of any dysnatremias over the 180-min exercise period, we calculated changes in the pre-to postexercise mass balance of sodium and potassium [(Na ϩ ϩ K ϩ )input-output ϭ EMB] and water (Vinput-Voutput ϭ VMB) through the sweat and urine, correcting for water intake over the final 2 h (11, 15). Finally, we used the equation presented in Kurtz and Nguyen (11, 15) to predict final S [Naϩ] from our data, using the early exercise P[Naϩ] sample (as opposed to the preexercise sample) to account for shifts in plasma volume and sodium during early exercise changes due to hydrostatic pressure:
where TBW is total body water.
Statistics. Data are expressed as means (SD) in all tables; however, for clarity, SEs are shown in graphs. We used two-way (group by hormone treatment) repeated-measures ANOVA models to test differences in the E MB and VMB due to group and hormone treatments. Differences between the groups across hormone conditions were tested using three-way (group by hormone by time) ANOVA for repeated measures. In all cases, where significant differences were found, orthogonal contrasts tested differences between specific means. We lacked sufficient statistical power to draw specific conclusions for interactions in our data so we looked for them and limited our conclusions accordingly. These interactions did not occur in our blood or urine variables of interest, with the exception of S [ALD] (see Fig. 3 ). Differences were considered statistically significant when P Ͻ 0.05. Data were analyzed using SPSS statistical software (SPSS, Chicago, IL).
Sample size calculation. Sample size calculations were based on our primary outcome variable of interest: responses of serum sodium concentration during exercise with drinking. The desired statistical test was two-sided, and we assumed an ␣-level equal to 0.01 to account for multiple comparisons (10) . There have been no controlled laboratory experiments to determine responses to water loading during exercise in women at risk for EAH, so we used the clinically meaningful effect size of S [Naϩ] of 5 meq/l and previously reported SD of 2.0 meq/l (24) to calculate statistical power. A sample size of seven women per group allowed us Ͼ80% statistical power (1 Ϫ ␤ Ͼ 0.80) to test within-group comparison to distinguish differences from chance alone. 7) and 39.9 (SD 2.9) ml ⅐kg Ϫ1 ⅐min Ϫ1 for Hypo and no Hypo, respectively. These V O 2peak levels are low for this age group of healthy women but are similar to those seen during recumbent bicycle testing in our laboratory (24) . Most of the subjects were physically active although none were athletes, and none of the subjects had prior experience with a recumbent bicycle. GnRH antagonist administration was associated with P [E2] and P [P4] similar to early follicular phase levels by 48 h in all 16 women (Table 1 , P Ͻ 0.05).
RESULTS

Although
During GnRH antagonist-alone treatment, one of the women in the no-Hypo group reported occasional breast tenderness, one of the subjects (no-Hypo group) reported occasional vasomotor symptoms ("hot flashes"), and one other subject (noHypo group) reported a mild headache. Subjects reported no other adverse effects due to the GnRH antagonist or hormone administration, and side effects did not cause any of the subjects to leave the study. After 4 days of transdermal estradiol administration, P [E2] increased by ϳ8-fold in both groups (P Ͻ 0.05). Following combined estradiol (12 days) with progesterone for 4 days, P [E2] remained increased by ϳ8-fold and P [P4] increased by ϳ10-to 12-fold (Table 1 , P Ͻ 0.05).
Baseline (preexercise). Preexercise cardiovascular and blood variables were similar between groups (Table 1 and Fig. 2) . Estradiol alone and combined estradiol-progesterone administration did not alter blood pressure, HR, or most fluid-regulating hormones in either group (Table 1 and Fig. 3 ) although progesterone administration increased preexercise S [ALD] in both groups (P Ͻ 0.05).
Preexercise P Osm , electrolytes, and P [AVP] were unaffected by group or treatment (Figs. 2 and 3) . However, preexercise Hct and Hb were lower during E 2 -P 4 treatments compared with both GnRH and E 2 within both groups (Table 1 , P Ͻ 0.05), suggesting some PV expansion related to the hormone treatments. Preexercise urine flow, U Osm , glomerular filtration rate (GFR), and renal electrolyte excretion were unaffected by group or hormone treatment ( Table 2) .
Exercise responses over the first 60 min (predrinking). The Hypo and no-Hypo groups lost similar body weight over the first 60 min of exercise, and the amount of body weight lost was independent of hormone treatment. Exercise increased P Osm , S [Naϩ] , and P [AVP] while decreasing PV similarly across groups and hormone treatments (Figs. 2 and 3) . Serum aldosterone and P [ANP] increased during exercise in both groups under all conditions, with S [ALD] during E 2 -P 4 treatment remaining above the GnRH antagonist alone and E 2 treatments within each group (Fig. 3 , P Ͻ 0.05). P [ANP] was elevated in the Hypo group during exercise over the no-Hypo group only with E 2 -P 4 ( Fig. 3 , P Ͻ 0.05). Sweating rates and sweat sodium concentration were similar across groups and hormone conditions, although sweat sodium concentration was greater in the Hypo group during E 2 -P 4 administration ( Table 3 , P Ͻ 0.05). Free water clearance (C H2O ) was unaffected by either group or hormone treatment during the first hour of exercise (Table 2) .
Moreover, all other renal variables examined were unaffected by group or hormone treatment during this early exercise period (Table 2 ). Blood pressure was unaffected in either group during the early exercise period across hormone treatments [mean blood pressure was 82 (SD 5) and 83 (SD 3) mmHg for no Hypo and Hypo, respectively].
Exercise with drinking. Cumulative drinking over the course of the final 2 h of exercise ranged from 32.8 to 43.1 ml/kg across the groups over the three experimental days. Drinking volume varied among the women because urine volume varied, and also because women in the Hypo group stopped drinking early if their S [Naϩ] fell below 129 meq/l or by Ͼ5 meq; and on two occasions drinking was stopped because the high water intake caused mild nausea in the no-Hypo subjects. Drinking volume was kept constant within each woman across treatment days. By 150 min of exercise (90 min of drinking) fluid intake was associated with lower P Osm and electrolytes relative to preexercise levels only in the Hypo group (Fig. 2 , P Ͻ 0.05). (24) 117 (8) 121 (12) 114 (5) 120 (9) 107 (17) DBP, mmHg 68 (15) 64 (2) 66 (10) 64 (6) 63 (14) 60 (3) MAP, mmHg 87 (17) 82 (4) 84 (9) 80 (5) 82 (12) 76 (5) HR, beats/min 70 (14) 67 (8) 72 (15) 73 (6) 68 (14) 74 (14) Data are expressed as means (SD); n ϭ 9 women for group with no history of hyponatremia (No Hypo), and n ϭ 7 women for group with history of at least one incident of hyponatremia (Hypo). Subjects were studied while taking gonadotropin-releasing hormone antagonist alone (GnRH Antagonist), while taking GnRH antagonist with estradiol (Estradiol), and while taking GnRH antagonist with estradiol ϩ progesterone (Estradiol-Progesterone). P͓E2͔, plasma concentration of estradiol; P͓P4͔, plasma concentration of progesterone; Hb, plasma concentration of hemoglobin; P͓ANP͔, plasma concentration of atrial natriuretic peptide; P͓AVP͔, plasma concentration of arginine vasopressin; S͓ALD͔, serum concentration of aldosterone; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial blood pressure. *Different from no-Hypo subjects. †Different from GnRH. ‡Different from Estradiol. Differences accepted at P Ͻ 0.05. Fig. 2 . Blood parameters for group with no history of hyponatremia (no Hypo; n ϭ 9) and group with history of hyponatremia (Hypo; n ϭ 7): plasma osmolality, serum concentrations of sodium ([Na ϩ ]) and potassium ([K ϩ ]), and change in plasma volume (from preexercise) during exercise in the heat before and during water ingestion (drink). Subjects were studied while taking GnRH antagonist alone, while taking GnRH antagonist with estradiol (Estradiol only), and while taking GnRH antagonist with estradiol ϩ progesterone (Estradiol-Progesterone). Data are expressed as means Ϯ SE. *Different from Hypo. Differences accepted at P Ͻ 0.05.
We stopped two women in the Hypo group because their S [Naϩ] fell by Ͼ5 meq/l, one of whom attained S [Naϩ] of 128 meq/l. P Osm and S [Naϩ] were lower in the Hypo group vs. the no-Hypo group after 150 min of exercise with drinking. Moreover, estimated PV recovery was more complete in the Hypo group during this last period of exercise with drinking ( Fig. 2 , P Ͻ 0.05). In contrast, the no-Hypo group maintained P Osm and S [Naϩ] at or near preexercise levels by 30 min of drinking.
Over the course of the entire exercise period, sodium sweat losses were unaffected by hormone treatment in either group (Table 4) , and there were no differences in overall sweat losses between the two groups under any of the hormone conditions, although ANOVA showed a trend for a group difference (P ϭ 0.07). Under all conditions, combined urine and sweat sodium loss was similar in Hypo [Ϫ85.6 (SD 36.2), Ϫ86.4 (SD 39.2), and Ϫ112.0 (SD 30.0) meq, P Ͻ 0.05] vs. no Hypo [Ϫ98.0 (SD 54.8), Ϫ80.9 (SD 57.6), and Ϫ105.1 (SD 46.4) meq for GnRH, E 2 , and E 2 -P 4 ] groups. Over the course of the entire exercise period, V MB was greater in the Hypo women during GnRH and E 2 treatment, although this was not the case during E 2 -P 4 (Table 4 , Fig. 4 , P Ͻ 0.05). Thus greater water retention explained most of the lower S [Naϩ] in the Hypo group compared with the no Hypo group (Table 4 and Fig. 4) . Equations (see METHODS) used to predict S [Naϩ] at the end of exercise indicate that these differences in E MB and V MB did not com- Fig. 3 . Fluid-regulating hormone responses for no Hypo (n ϭ 9) and Hypo (n ϭ 7) groups. Plasma concentrations of arginine vasopressin (P[AVP]) and atrial natriuretic peptide (P[ANP]) and serum aldosterone (S[ALD],) during exercise in the heat before and during water ingestion (drink). Subjects were studied while taking GnRH antagonist alone, while taking GnRH antagonist with estradiol, and while taking GnRH antagonist with estradiol ϩ progesterone. Data are expressed as means Ϯ SE. *Different from no Hypo. †Different from GnRH antagonist alone within both groups. #Different from no Hypo within estradiol only. ␦Different from estradiol-progesterone and both other treatments within groups. Differences accepted at P Ͻ 0.05. Data are expressed as means (SD); n ϭ 9 women for no-Hypo group, and n ϭ 7 women for Hypo group. Subjects were studied while taking GnRH antagonist alone, while taking GnRH antagonist with estradiol, and while taking GnRH antagonist with estradiol ϩ progesterone. GFR, glomerular filtration rate; Uv, urine flow; U Na ϩ , urine sodium excretion (urine flow rate (ml/min) ϫ time ϫ urine sodium concentration); UOsm, urine osmolality; CH2O, renal free water clearance; COsm, osmotic clearance.
pletely explain the fall in S [Naϩ] (11, 13, 15) , most notably within the Hypo groups during E 2 -P 4 . Hormone treatment did not impact overall water regulation in the no-Hypo group (Figs. 4 and 5) .
Although S [ALD] remained elevated relative to preexercise levels for both groups under all hormone conditions during drinking, S [ALD] was lower in the Hypo vs. no-Hypo group within each hormonal condition (Fig. 3, P Ͻ 0.05) . Moreover, S [ALD] remained elevated during E 2 -P 4 treatment within each group throughout the exercise period ( Fig. 3 , P Ͻ 0.05). Neither group nor hormone condition impacted renal function or electrolyte excretion during this drinking phase of exercise (Table 2 ). Blood pressure was unaffected in either group during the drinking period across hormone treatments [mean blood pressure was 85 (SD 4) and 78 (SD 4) mmHg for no Hypo and Hypo, respectively].
DISCUSSION
This is the first study to prospectively examine risk factors for EAH in women in a controlled laboratory setting. Our protocol reproduced EAH in women susceptible to it, but was not so extreme as to cause EAH in women with low risk of EAH, suggesting that a previous episode of EAH, or another type of hyponatremia (1 subject) is a risk factor for future events. Importantly, sex hormone manipulation did not contribute to the fall in S [Naϩ] . Within the Hypo women, mass balance equations demonstrated a more positive V MB , and more water retention in the vascular compartment explained most of the hyponatremia observed across all hormone conditions. Despite the similar S [Naϩ] within the Hypo women under all hormone conditions, we found a greater fall in E MB during E 2 -P 4 , suggesting sodium loss may contribute to EAH in women during increased progesterone exposure.
Our drinking protocol over the last 120 min of exercise induced a dramatic fall in P Osm and P [Naϩ] only in the women at risk for EAH, which was accompanied by mild body weight gain and water retention. In contrast, P Osm and P [Naϩ] were similar to baseline levels in the women at low risk for EAH. Although PV was not restored completely to baseline levels in either group, drinking led to greater plasma volume recovery during exercise in the high-risk EAH group relative to the low-risk EAH group. This earlier and more complete restoration of PV in the high-risk EAH group likely played a role in their lower P [Naϩ] .
We used equations from Kurtz and Nguyen to determine the causes for the greater fall in plasma sodium concentration in the hyponatremic group and to predict changes in S [Naϩ] (11, 15) . Although our protocol forced similar fluid intake between the groups relative to body weight, the lower body mass index in the Hypo group indicates lower baseline body water relative to the no-Hypo group, suggesting that the drinking challenge was indeed greater in the Hypo women. Given the similar Data are presented as means (SD); n ϭ 8 women for no-Hypo group, and n ϭ 7 women for Hypo group. Subjects were studied while taking GnRH antagonist alone, while taking GnRH antagonist with estradiol, and while taking GnRH antagonist with estradiol ϩ progesterone. *Different from no-Hypo subjects. Data are presented as means (SD); n ϭ 9 women for no-Hypo group, and n ϭ 7 women for Hypo group. Subjects were studied while taking GnRH antagonist alone (GnRH ant), while taking GnRH antagonist with estradiol (E2), and while taking GnRH antagonist with estradiol ϩ progesterone (E2-P4). Total body water is estimated as 0.63 ϫ body wt (kg). Cumulative parameters are the sum of the 3 h of exercise. Mass balance and electrolyte pools were estimated using the equations in Kurtz and Nguyen (11, 15) and to predict changes in S[Naϩ]. *Different from no Hypo. †Different from GnRH antagonist alone within Hypo. ‡Different from estradiol within Hypo only.
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WATER AND SODIUM REGULATION IN HYPONATREMIA magnitude of the negative E MB between groups, a similar volume of water overload in smaller women may induce an exaggerated fall in plasma sodium regardless of the magnitude of the sodium deficit. Thus the positive V MB caused the large fall in S [Naϩ] independent of changes in electrolyte status. Therefore, our data point to excessive water drinking relative to a smaller body size as a primary cause for hyponatremia in women susceptible to it.
Within the Hypo group, overall sodium loss was greater and E MB and V MB more negative in E 2 -P 4 compared with the other two hormone treatments. However, S [Naϩ] was similar across all hormone treatments. This maintenance of S [Naϩ] despite greater sodium losses was also associated with early restoration of plasma volume and is consistent with our earlier findings and those of others demonstrating that progesterone can impact transcapillary forces to alter extracellular fluid distribution (18, 23, 26) . The progesterone effects on transcapillary forces within the extracellular space are especially obvious during elevations in P [ANP] (23) . In an earlier study in resting women, E 2 -P 4 prevented the PV losses normally associated with ANP infusion by decreasing capillary filtration coefficient (CFC) and attenuating transcapillary fluid movement out of the vasculature (23) . The lower plasma protein concentration (P [P] ) under both the E 2 and E 2 -P 4 treatments (Fig. 5 ) suggest that oncotic forces should have led to fluid movement out of the vascular space and into the interstitium, but rather than lowering PV, the opposite occurred under all three conditions in the Hypo women. In our previous study, a similar protection of PV and decrease in CFC were independent of changes in plasma proteins, oncotic pressure, sodium excretion, or body weight. From these earlier findings we concluded that progesterone blunts ANP-induced PV loss by altering transcapillary forces rather than through changes in sodium retention. In the present study, P [ANP] was elevated in Hypo women during E 2 -P 2 relative to GnRH antagonist alone during drinking so may extend our resting findings to exercise. Thus during exercise progesterone exposure may limit the ANP-related rise in CFC and capillary permeability, thereby protecting PV and S [Naϩ] even when conditions favor fluid movement out of the vascular space (i.e., lower P [P] ). Clearly studies directly studying the interaction of ANP, exercise, and transcapillary fluid dynamics in women at risk for EAH would be required to address this hypothesis. Another explanation for the similar S [Naϩ] across the hormone conditions in which E MB differed could be inherent in our study design which required stopping exercise at a safe sodium concentration to protect subjects from extreme EAH.
Under all three hormone conditions, S [ALD] was lower in the high-risk EAH women relative to the low-risk EAH women, which would have been consistent with greater sweat sodium and urine losses in the latter group. Within the no-Hypo group, there was little difference in sodium loss (urine or sweat) across hormone conditions despite the greater S [ALD] , similar to our previous findings both in the midluteal phase of the menstrual cycle and during progesterone administration (22) , and is consistent with the common finding of a progesteronemediated inhibition of aldosterone-dependent sodium reabsorption at distal sites in the nephron (3, 12, 21, 24) . This transient natriuresis produces a compensatory stimulation of the renin-angiotensin-aldosterone system (14) , so perhaps the Hypo women are slightly more sensitive to aldosterone. However, with regard to alterations in overall sodium and fluid regulation, women in the high-risk EAH group demonstrated greater sodium losses when progesterone was present.
In summary, previous experience with a hyponatremic event was a good predictor for EAH in healthy young women. The relative EAH in the high-risk women was primarily a function of water retention associated with excessive water drinking. As found in other studies examining sex differences in EAH risks, Fig. 4 . Mass balance of sodium and potassium (EMB) and water (VMB) from 10 min of exercise to 180 min of exercise for no Hypo (n ϭ 9) and Hypo (n ϭ 7) groups. EMB and VMB were calculated using the equations presented in Kurtz (11) and Nguyen (15) . Data are expressed as means Ϯ SE. *Different from no Hypo. †Different from GnRH alone. ␥Different from estradiol within Hypo only. Differences accepted at P Ͻ 0.05. Fig. 5 . Plasma protein concentration (P[P]) for no Hypo (n ϭ 9) and Hypo (n ϭ 7) groups. Subjects were studied while taking GnRH antagonist alone, while taking GnRH antagonist with estradiol, and while taking GnRH antagonist with estradiol ϩ progesterone. Data are expressed as means Ϯ SE. *Different from no Hypo. †Different from GnRH antagonist alone within Hypo. Differences accepted at P Ͻ 0.05. a major difference between the two groups was body size. It is quite likely that the smaller body size in Hypo women exaggerated the impact of excessive water loads as well as sodium loss during exercise. Although E MB was more negative during progesterone exposure in at-risk women, S [Naϩ] was similar across hormone treatments within this group. The effects of progesterone on transcapillary fluid dynamics or our control of fluid intake in these studies may explain this apparent discrepancy.
Perspectives
During long-distance events, maintaining adequate hydration is essential to avoid heat-associated disorders. In an attempt to ensure adequate hydration, many participants drink excessive amounts of hypotonic fluids. However, very few athletes experience EAH, and only in a small subsection does the EAH progress to symptoms or dangerous outcomes (19, 20, 27) . Our findings suggest that in women susceptible to EAH more fluid is retained and more sodium lost when both estradiol and progesterone are elevated. Because these women are at greater risk for EAH and become symptomatic (based on their past experience), knowledge of hormone status in women during field studies of hyponatremia may prove helpful in determining mechanisms for EAH. Moreover, during longterm exercise we should take special care to monitor fluid and electrolytes in women susceptible to symptomatic hyponatremia (e.g., those with a history of hyponatremia) when both estrogen and progesterone are elevated, such as during pregnancy, while taking oral contraceptives, and during the luteal phase of the menstrual cycle.
